Cargando…

Estimated public health impact of human rotavirus vaccine (HRV) and pneumococcal polysaccharide protein D-conjugate vaccine (PHiD-CV) on child morbidity and mortality in Gavi-supported countries

Vaccine impact models against rotavirus disease (RD) and pneumococcal disease (PD) in low- and middle-income countries assume vaccine coverage based on other vaccines. We propose to assess the impact on severe disease cases and deaths avoided based on vaccine doses delivered by one manufacturer to G...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marijam, Alen, Schuerman, Lode, Izurieta, Patricia, Pereira, Priya, Van Oorschot, Désirée, Mehta, Shailesh, Ota, Martin OC, Standaert, Baudouin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2022
Materias:	Public Health – Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9766466/ https://www.ncbi.nlm.nih.gov/pubmed/36507685 http://dx.doi.org/10.1080/21645515.2022.2135916

Ejemplares similares

Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea
por: Zhang, Xu-Hao, et al.
Publicado: (2017)

Exploring the evidence behind the comparable impact of the pneumococcal conjugate vaccines PHiD-CV and PCV13 on overall pneumococcal disease
por: Izurieta, Patricia, et al.
Publicado: (2021)

Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial
por: Dicko, Alassane, et al.
Publicado: (2011)

Safety, reactogenicity and immunogenicity of a booster dose of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children
por: Dicko, Alassane, et al.
Publicado: (2013)

Effectiveness of the 10-Valent Pneumococcal Nontypeable Haemophilus influenzae Protein D–Conjugated Vaccine (PHiD-CV) Against Carriage and Acute Otitis Media—A Double-Blind Randomized Clinical Trial in Finland
por: Vesikari, Timo, et al.
Publicado: (2016)

Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life
por: Odusanya, Olumuyiwa O, et al.
Publicado: (2014)

Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial
por: Tregnaghi, Miguel W., et al.
Publicado: (2014)

Overall effectiveness of pneumococcal conjugate vaccines: An economic analysis of PHiD-CV and PCV-13 in the immunization of infants in Italy
por: Castiglia, Paolo, et al.
Publicado: (2017)

Correction: Efficacy of Pneumococcal Nontypable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) in Young Latin American Children: A Double-Blind Randomized Controlled Trial
por: Tregnaghi, Miguel W., et al.
Publicado: (2015)

Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study
por: Dicko, Alassane, et al.
Publicado: (2015)

Cost-effectiveness analysis of a universal mass vaccination program with a PHiD-CV 2+1 schedule in Malaysia
por: Wang, Xiao Jun, et al.
Publicado: (2017)

Effects of Vaccination with 10-Valent Pneumococcal Non-Typeable Haemophilus influenza Protein D Conjugate Vaccine (PHiD-CV) on the Nasopharyngeal Microbiome of Kenyan Toddlers
por: Feazel, Leah M., et al.
Publicado: (2015)

Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model
por: Delgleize, Emmanuelle, et al.
Publicado: (2016)

A 6-year safety surveillance of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in South Korea
por: Lee, Soon Min, et al.
Publicado: (2018)

10‐valent pneumococcal non‐typeable Haemophilus influenzae protein‐D conjugate vaccine (PHiD‐CV) induces memory B cell responses in healthy Kenyan toddlers
por: Muema, D. M., et al.
Publicado: (2015)

Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study
por: Iwata, Satoshi, et al.
Publicado: (2015)

A cost-effectiveness analysis of PHiD-CV compared to PCV13 in a national immunization program setting in Tunisia
por: Lagoubi, Youness, et al.
Publicado: (2022)

Pneumonia hospitalizations and mortality in children 3 – 24-month-old in Nigeria from 2013 to 2020: Impact of pneumococcal conjugate vaccine ten valent (PHiD-CV-10)
por: Iliya, Jalo, et al.
Publicado: (2023)

A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzaeprotein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia
por: Lim, Fong Seng, et al.
Publicado: (2014)

A Cost-Effectiveness Analysis of the 10-Valent Pneumococcal Non-Typeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Compared to the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) for Universal Mass Vaccination Implementation in New Zealand
por: Varghese, Lijoy, et al.
Publicado: (2018)

Serotype changes and antimicrobial nonsusceptibility rates of invasive and non-invasive Streptococcus pneumoniae isolates after implementation of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Bulgaria
por: Setchanova, Lena, et al.
Publicado: (2017)

Health and economic impact of rotavirus vaccination in GAVI-eligible countries
por: Kim, Sun-Young, et al.
Publicado: (2010)

How to assess for the full economic value of vaccines? From past to present, drawing lessons for the future
por: Standaert, Baudouin, et al.
Publicado: (2020)

phiD12-Like Livestock-Associated Prophages Are Associated With Novel Subpopulations of Streptococcus agalactiae Infecting Neonates
por: Renard, Adélaïde, et al.
Publicado: (2019)

Effects of prophylactic ibuprofen and paracetamol administration on the immunogenicity and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugated vaccine (PHiD-CV) co-administered with DTPa-combined vaccines in children: An open-label, randomized, controlled, non-inferiority trial
por: Falup-Pecurariu, Oana, et al.
Publicado: (2016)

Vaccine comprising live attenuated or inactivated rotavirus strains; HRV 89-12C2, HRV 408, HRV 248 HRV 456 and/or CJN, for immunization against rotavirus illnesses
Publicado: (1992)

The Economic Value of Rotavirus Vaccination When Optimally Implemented in a High-Income Country
por: Standaert, Baudouin
Publicado: (2023)

Summary of WG7 at CKM 2018: "Mixing and $CP$ violation in the $D$ system: $x_D$, $y_D$, $|q/p|_D$, $\phi_D$, and direct $CP$ violation in $D$ decays"
por: Bhardwaj, Vishal, et al.
Publicado: (2019)

Defining the Recipe for an Optimal Rotavirus Vaccine Introduction in a High-Income Country in Europe
por: Standaert, Baudouin, et al.
Publicado: (2022)

10-Valent pneumococcal non-typeable H. influenzae protein D conjugate vaccine (PHiD-CV10) versus 13-valent pneumococcal conjugate vaccine (PCV13) as a booster dose to broaden and strengthen protection from otitis media (PREVIX_BOOST) in Australian Aboriginal children: study protocol for a randomised controlled trial
por: Oguoma, Victor M, et al.
Publicado: (2020)

Cost effectiveness and budget impact of universal varicella vaccination in Russia
por: Marijam, Alen, et al.
Publicado: (2022)

Lessons Learned from Long-Term Assessment of Rotavirus Vaccination in a High-Income Country: The Case of the Rotavirus Vaccine Belgium Impact Study (RotaBIS)
por: Standaert, Baudouin, et al.
Publicado: (2020)

Re-evaluating the potential impact and cost-effectiveness of rotavirus vaccination in 73 Gavi countries: a modelling study
por: Debellut, Frédéric, et al.
Publicado: (2019)

Le vaccin antipaludique RTS,S/AS01 chez les enfants âgés de 5 à 17 mois au moment de la première vaccination
por: Vandoolaeghe, Pascale, et al.
Publicado: (2018)

Will vaccination against rotavirus infection with RIX4414 be cost-saving in Germany?
por: Knoll, Stefanie, et al.
Publicado: (2013)

Improving the Hospital Quality of Care during Winter Periods by Optimizing Budget Allocation Between Rotavirus Vaccination and Bed Expansion
por: Dort, Thibaut, et al.
Publicado: (2017)

Medium- to Long-Term Impact of Rotavirus Vaccination on Hospital Care in Belgium: A 7-Year Follow-Up of the Rotavirus Belgium Impact Study (RotaBIS)
por: Standaert, Baudouin, et al.
Publicado: (2015)

Comment on Postma et al. Predicted Public Health and Economic Impact of Respiratory Syncytial Virus Vaccination with Variable Duration of Protection for Adults ≥60 Years in Belgium. Vaccines 2023, 11, 990
por: Standaert, Baudouin
Publicado: (2023)

Health and economic benefits of single-dose HPV vaccination in a Gavi-eligible country
por: Burger, Emily A., et al.
Publicado: (2018)

Experiences of operational costs of HPV vaccine delivery strategies in Gavi-supported demonstration projects
por: Botwright, Siobhan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bl53arm9hgspf7dg10ebes3lch